AirSculpt Technologies Inc

Análisis de la acción AirSculpt Technologies Inc (AIRS)

$1.275

-0.126 (-9.89%)Al cierre

Loading chart…
Máximo
1.430
Apertura
1.430
Precio medio ponderado por volumen
1.31
Volumen
1.15M
Capitalización
236.04M
Mínimo
1.240
Importe
1.52M
EV/EBITDA, TTM
12.65

AirSculpt Technologies, Inc. is engaged in providing body contouring treatment. The Company's treatment procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for healing with minimal bruising, tighter skin, and precise results. It offers a range of fat removal procedures across treatment areas. It also offers fat transfer procedures that use the patient’s own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its body contouring procedures include the Power BBL, a Brazilian butt lift procedure, the Up a Cup, a breast enhancement procedure, and the Hip Flip, an hourglass contouring procedure. It also offers AirSculpt +, which permanently removes fat and tightens the skin. Its treatment combines helium gas and radiofrequency energy to create a plasma equipped to correct sagging skin and restore a youthful, natural appearance.

airsculpt.com

Análisis de IA of AirSculpt Technologies Inc (AIRS)

Mantener

Airsculpt Technologies Inc is currently not a strong buy due to its low current price of $1.275 and a very low RSI of 11.478, indicating oversold conditions. While analysts have set a price target of $5, the stock has experienced a significant decline of 87.66% over the past year, which raises concerns about its stability. The main risk is its negative earnings per share (EPS) of -0.02, which reflects ongoing financial struggles despite some improvements in gross margin to 54.39%.

Métricas de valoración

El PER previsto actual de AirSculpt Technologies Inc (AIRS) es 0.00, frente a su media de 5 años de 63.22.

PER previsto

Valor razonable
Media 5A P/E
63.22
P/E actual
0.00
Sobrevalorada
358.74
Infravalorada
-232.30

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
18.56
EV/EBITDA actual
12.65
Sobrevalorada
38.18
Infravalorada
-1.05

Precio/ventas previsto

Infravalorado
Media 5A P/S
2.01
P/S actual
0.66
Sobrevalorada
3.07
Infravalorada
0.96

Escenarios de precio de Alphio AI para AIRS

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%AIRS

$4.14

Precio del escenario

B

Base

Base · 50%AIRS

$3.25

Precio del escenario

B

Bajista

Bajista · 25%AIRS

$2.81

Precio del escenario

Cronología de eventos

2026-08-10 (ET)

06:30:00

Company Reports Q2 Revenue of $42.9M, Below Expectations

06:30:00

2026 Revenue Consensus at $153.19M, Adjusted EBITDA View Reduced to $12M-$14M

2026-05-08 (ET)

06:40:00

Reaffirms FY26 Adjusted EBITDA View of $15M-$17M

06:40:00

AirSculpt Reports Q1 Revenue of $39.39M

2026-04-02 (ET)

16:40:00

Major U.S. Averages Mixed as Oil Prices Rise to $111.54

Noticias

Preguntas frecuentes sobre AIRS, respondidas por Alphio AI

AirSculpt Technologies, Inc. is engaged in providing body contouring treatment. The Company's treatment procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for healing with minimal bruising, tighter skin, and precise results. It offers a range of fat removal procedures across treatment areas. It also offers fat transfer procedures that use the patient’s own fat cells to enhance the breasts, buttocks, hips or other areas and do not require silicone or foreign materials to be implanted. Its body contouring procedures include the Power BBL, a Brazilian butt lift procedure, the Up a Cup, a breast enhancement procedure, and the Hip Flip, an hourglass contouring procedure. It also offers AirSculpt +, which permanently removes fat and tightens the skin. Its treatment combines helium gas and radiofrequency energy to create a plasma equipped to correct sagging skin and restore a youthful, natural appearance. It operates in the Healthcare sector (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE industry).

Airsculpt Technologies Inc is currently not a strong buy due to its low current price of $1.275 and a very low RSI of 11.478, indicating oversold conditions. While analysts have set a price target of $5, the stock has experienced a significant decline of 87.66% over the past year, which raises concerns about its stability. The main risk is its negative earnings per share (EPS) of -0.02, which reflects ongoing financial struggles despite some improvements in gross margin to 54.39%.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar